Search results for "Color"

showing 10 items of 2721 documents

Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses

1995

In echocardiographic and necropsy studies nodular thickening of the mitral valve and, less frequently, of the aortic valve has been found in 60%-90% of patients with mucopolysaccharidoses (MPS). Little is known about the haemodynamic consequences of these morphological changes. In this study 84 unselected patients with different enzymatically proven MPS and 84 age and sex matched, healthy persons were studied prospectively by colour Doppler flow mapping. The patients' age ranged from 1 to 47 years (median 8.1 years). Mitral and aortic regurgitation were defined as a holosystolic or holodiastolic jet originating from the valve into the left atrium or the left ventricular outflow tract, respe…

AdultMaleAortic valvemedicine.medical_specialtyAdolescentAortic Valve InsufficiencyHemodynamicsRegurgitation (circulation)Doppler echocardiographyMitral valveInternal medicinemedicineHumansVentricular outflow tractProspective Studiescardiovascular diseasesChildskin and connective tissue diseasesMitral regurgitationmedicine.diagnostic_testbusiness.industryInfantMitral Valve InsufficiencyMiddle AgedMucopolysaccharidosesEchocardiography Doppler ColorSurgerymedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child Healthcardiovascular systemCardiologyFemaleComplicationbusinessEuropean Journal of Pediatrics
researchProduct

RUPTURE OF A LEFT SINUS OF VALSALVA ANEURYSM INTO THE PULMONARY ARTERY.

2006

Sinus of Valsalva aneurysm is a rare congenital defect and the diagnosis is usually made after it ruptures. Very few cases of non-complicated sinus of Valsalva aneurysm have been published. The anomaly most often involves the right coronary sinus and less frequently the non-coronary sinus. A case with left sinus of Valsalva has not been reported. Since the aortic valve occupies a central position in the base of the heart, rupture of a sinus of Valsalva aneurysm can occur in any of the four heart chambers. Rupture into the pulmonary artery is very rare and is mostly associated with other congenital cardiopathies. ª 2005 The European Society of Cardiology. Published by Elsevier Ltd. All right…

AdultMaleAortic valvemedicine.medical_specialtyHeart.chambersAneurysm RupturedPulmonary ArteryMyocardial ruptureDiagnosis DifferentialAneurysmInternal medicinemedicine.arteryHIV Seropositivityotorhinolaryngologic diseasesHumansMedicineRadiology Nuclear Medicine and imagingcardiovascular diseasesHeart AneurysmSinus (anatomy)Coronary sinusbusiness.industryGeneral MedicineSinus of Valsalvamedicine.diseaseAneurysmEchocardiography Doppler Colorbody regionsmedicine.anatomical_structurePulmonary arterycardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyRupture into the pulmonary artery
researchProduct

Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods

2013

Net survival, the survival which might occur if cancer was the only cause of death, is a major epidemiological indicator required for international or temporal comparisons. Recent findings have shown that all classical methods used for routine estimation of net survival from cancer-registry data, sometimes called "relative-survival methods," provide biased estimates. Meanwhile, an unbiased estimator, the Pohar-Perme estimator (PPE), was recently proposed. Using real data, we investigated the magnitude of the errors made by four "relative-survival" methods (Ederer I, Hakulinen, Ederer II and a univariable regression model) vs. PPE as reference and examined the influence of time of follow-up,…

AdultMaleCancer ResearchLung NeoplasmsAdolescent[SDV]Life Sciences [q-bio]Breast NeoplasmsRisk Assessment03 medical and health sciencesAge Distribution0302 clinical medicineBreast cancerBiasBias of an estimatorRisk FactorsCause of DeathNeoplasmsStatisticsmedicineHumansRegistriesThyroid Neoplasms030212 general & internal medicineSurvival analysisAgedMathematicsEstimationModels StatisticalRelative survivalIncidenceAge FactorsProstatic NeoplasmsCancerEstimatorRegression analysisMiddle AgedPrognosismedicine.diseaseHodgkin DiseaseSurvival Analysis3. Good healthOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleFranceColorectal Neoplasms
researchProduct

Elevated serum E-selectin in patients with liver metastases of colorectal cancer

1996

E-selectin, an endothelial cell adhesion molecule, mediates the initial step of leucocyte adhesion to activated vascular endothelium. The soluble isoform of E-selectin promotes angiogenesis in rat cornea. In the present study, we investigated whether leucocyte adhesion and angiogenesis are also involved in tumour progression and metastasis of colorectal cancer. Therefore, we determined the level of circulating soluble E-selectin in serum samples of 38 patients with colorectal cancer; 20 patients with non-metastatic and 18 patients with metastatic disease. Median levels of soluble E-selectin were found to be significantly higher in metastatic tumour disease (88.7 ng/ml, range 25-203 ng/ml) t…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAngiogenesisColorectal cancerFibrinogenMetastasisE-selectinmedicineCarcinomaHumansAgedbiologyTumor Necrosis Factor-alphaCell adhesion moleculebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplasm ProteinsC-Reactive ProteinSolubilityOncologyTumor progressionCancer researchbiology.proteinFemaleColorectal NeoplasmsE-Selectinbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression

1997

Nm23 gene codifies for a nucleoside diphosphate kinase allowing the intracellular transduction of the signals. In colorectal cancer nm23 protein expression seems related to the progression of the disease. By immunohistochemistry we have studied the intracytoplasmatic nm23 H1 protein expression in 20 patients affected by colorectal cancer at initial stage. In 12 cases it resulted elevated and in four the disease recurred. The overexpression was not correlated with other prognostic factors. Nm23 H1-positive patients affected by colorectal cancer at initial stage could be considered at risk for disease recurrence and included in a more frequent follow-up protocol.

AdultMaleCancer ResearchPathologymedicine.medical_specialtyColorectal cancerRectumDiseaseMouse model of colorectal and intestinal cancerGene expressionBiomarkers TumormedicineCarcinomaHumansAgedMonomeric GTP-Binding ProteinsNeoplasm StagingAged 80 and overbusiness.industryMiddle AgedNM23 Nucleoside Diphosphate KinasesPrognosismedicine.diseaseNucleoside-diphosphate kinaseNeoplasm Proteinsmedicine.anatomical_structureOncologyNucleoside-Diphosphate KinaseDisease ProgressionCancer researchImmunohistochemistryFemaleColorectal NeoplasmsbusinessTranscription FactorsCancer Letters
researchProduct

Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma

2004

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyProliferation indexColorectal cancerSettore MED/08 - Anatomia PatologicaThymidylate synthase expressionThymidylate synthaseSignet ring cell carcinomaSignet ring cell carcinomaCarcinomamedicineHumansThymidylate synthase expression; Signet ring cell carcinoma; Colorectal carcinoma; ImmunohistochemistryAgedbiologySignet ring cellThymidylate SynthaseMiddle AgedCell cyclemedicine.diseaseImmunohistochemistrydigestive system diseasesNeoplasm ProteinsColorectal carcinomaKi-67 AntigenOncologybiology.proteinCancer researchSettore BIO/14 - FarmacologiaImmunohistochemistryFemaleColorectal NeoplasmsCarcinoma Signet Ring Cell
researchProduct

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

2016

Rectal cancer is a common and serious disease. The aim of the SUDCAN collaborative study was to compare the net survival from rectal cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study-period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses …

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualEpidemiologyColorectal cancer03 medical and health sciencesYoung Adult0302 clinical medicineBelgiumEpidemiologymedicineHumansRegistriesYoung adultSurvival rateNet SurvivalMass screeningAgedExcess mortalityAged 80 and overPortugalbusiness.industryRectal NeoplasmsPublic Health Environmental and Occupational HealthMiddle Agedmedicine.disease3. Good healthPopulation based studyEuropeSurvival RateOncologyItalySpain030220 oncology & carcinogenesisPopulation Surveillance030211 gastroenterology & hepatologyFemaleFrancebusinessSwitzerlandDemographyEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorecta…

2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5-fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27-79 years) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy, an irinotecan-based second-line regimen, and a third-line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5-FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The respo…

AdultMaleCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryOxaliplatinIrinotecanBevacizumabRegimenBevacizumabcolorectal cancerOncologyDrug Resistance NeoplasmRetreatmentFemaleFluorouracilbusinessBevacizumab; Colorectal cancer; cancer combination chemotherapyColorectal Neoplasmsmedicine.drug
researchProduct

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

2008

Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan. Experimental Design: Sixty-eight heavily pretreated metastatic colorectal cancer patients were evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and 1, 7, 14, 21, 50, and 92 days after the start of treatment. Results: Basal Mg2+ median levels were significan…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCetuximabmagnesiumcolorectal cancerAntibodies Monoclonal HumanizedIrinotecanGastroenterologyHypomagnesemiaBasal (phylogenetics)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMagnesiumEpidermal growth factor receptorNeoplasm MetastasisAgedAged 80 and overCetuximabbiologybusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseIrinotecanGene Expression Regulation NeoplasticEndocrinologyTreatment OutcomeOncologyMonoclonalbiology.proteinDisease ProgressionCamptothecinFemalebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.

1992

A phase II trial of citrovorum factor, 500 mg/m2/week, plus 5-fluorouracil, 400 mg/m2/week on day 1, and cisplatin, 20 mg/m2/week on day 2, was carried out in a group of 40 patients with metastatic colorectal carcinoma. A partial response with a mean duration of 8.4+ months was achieved in 24% of patients, a minimal response with a mean duration of 5.4 months was obtained in 6% of patients, and a stabilization of 6.2 months was achieved in 41%. Ten patients (29%) progressed. A 38% partial response rate was seen in patients with advanced rectal carcinoma, whereas no response was obtained in patients with colon cancer. Interestingly, 5 partial responses were seen in 12 patients pretreated wit…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCitrovorum factorLeucovorinGastroenterologyDrug Administration ScheduleInternal medicinePartial responseRectal carcinomaAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansIn patientAgedCisplatinbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgeryOncologyFluorouracilDrug EvaluationFemaleFluorouracilCisplatinbusinessColorectal Neoplasmsmedicine.drugCancer investigation
researchProduct